MTOR Kinase Inhibitor PP242

CI-DRUG-00000366Explore in graph →NCIt C128632 CIViC

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Data not yet available

No registered interventional trial or approval record places this drug in the pipeline yet.

Curated evidence

Clinical evidence (5)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–5 of 5 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
ERBB2 Amplification1
MTOR Kinase Inhibitor PP242

Clinical trials

Trials with this intervention (0)

Data not yet available

No registered study lists this drug as an intervention yet.

PIK3CA Mutation1
Everolimus + MTOR Kinase Inhibitor PP242Substitutes	Malignant Breast Neoplasm	Predictive	D	Supports Sensitivity Response	3	accepted	EID1610 A panel of 31 breast cancer cell lines was tested for sensitivity to mTORC1 inhibitor everolimus and mTORC1/mTORC2 inhibitor PP242. Inhibitor concentrations for 50% survival fraction (SF50) were measu… (full text at CIViC) PMID 21358673 · Weigelt et al., 2011 · Open in CIViC	civic

PIK3R1 Mutation1
MTOR Kinase Inhibitor PP242	Malignant Breast Neoplasm	Predictive	D	Supports Sensitivity Response	2	accepted	EID1612 Sensitivity to mTORC1/2 inhibitor PP242 was assessed in a panel of breast cancer cell lines with various mutation backgrounds. PTEN and PIK3CA mutations were heavily represented in the panel. However,… (full text at CIViC) PMID 21358673 · Weigelt et al., 2011 · Open in CIViC	civic

PTEN Loss1
Everolimus + MTOR Kinase Inhibitor PP242Substitutes	Malignant Breast Neoplasm	Predictive	D	Does Not Support Sensitivity Response	3	accepted	EID1611 In a panel of 31 breast cancer cell lines, 11 had loss of PTEN function. Cells were tested for sensitivity to mTORC1 inhibitor everolimus and mTORC1/2 inhibitor PP242, and no significant correlation w… (full text at CIViC) PMID 21358673 · Weigelt et al., 2011 · Open in CIViC	civic

EIF4EBP1 PHOSPHORYLATION1
Dactolisib + MTOR Kinase Inhibitor PP242 + WYE354Substitutes	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	D	Supports Resistance	2	accepted	EID932 12 CRC cell lines were evaluated. 40% of these were intrinsically resistant to mTOR inhibition with BEZ235, PP242 or WYE354. mTOR independent phosphorylation of EIF4EBP1 (T37/46) was associated with … (full text at CIViC) PMID 22262166 · Zhang et al., 2012 · Open in CIViC	civic